Liver and biliary tract cancer trials in Japan

In Japan 35 Also abroad 1314

35 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Chiba, Kyoto
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 1/2Taking people
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Where
Kashiwa, Yokohama
Age
18 years and over
People
220 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00
No phaseTaking people
Observational Study Protocol: LIVER-R
Where
Kanazawa, Kashiwa-shi, Kurume, Kyoto, Nagoya, Ōsaka-sayama, Sendai, Yokohama
Age
18 years to 130 years
People
4,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT06252753
Phase 3Taking people
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Where
Bunkyō-Ku, Chiba, Chuo Ku, Fukuoka, Kagoshima, Kanazawa, Kashiwa, Koto-ku, Kyoto, Matsuyama, Mitaka-shi, Nagoya, Niigata, Osaka, Sapporo, Sendai, Suita-shi, Tsu, Ube-shi, Yokohama
Age
18 years and over
People
286 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Where
Kashiwa, Osakasayama-shi
Age
18 years and over
People
198 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00
Phase 1Taking people
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
Where
Kashiwa, Tokyo
Age
18 years and over
People
148 worldwide
Run by
Bayer
See details and how to joinNCT06764316 · EU 2024-516615-25-00
No phaseTaking people
TheraSphere Japan Pre-Market Study
Where
Chuo Ku, Kanazawa, Kashihara, Nishinomiya, Sayama
Age
18 years and over
People
51
Run by
Boston Scientific Corporation
See details and how to joinNCT07377487
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Phase 1/2Taking people
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Where
Kashiwa, Yokohama
Age
18 years and over
People
304 worldwide
Run by
AstraZeneca
See details and how to joinNCT06795022 · EU 2024-516698-56-00
Phase 3Taking people
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Where
Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi, Kitaadachi-gun, Kita-gun, Kōtoku, Kumamoto, Kurashiki-shi, Kyoto, Maebashi, Mitaka-shi, Nagoya, Osaka, Sakaishi, Sapporo, Sendai, Shinjuku-ku, Suita, Sunto-gun, Ube-shi, Wakayama, Yokohama
Age
18 years to 99 years
People
620 worldwide
Run by
AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00
Phase 3Taking people
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Where
Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe, Kōtoku, Kumamoto, Kurume-shi, Kyoto, Matsuyama, Mitaka-shi, Morioka, Musashino-shi, Nagoya, Okayama, Osaka, Osakasayama-shi, Saga, Sapporo, Sendai, Suita-shi, Tokyo, Toyoake-shi, Tsu, Yokohama
Age
18 years and over
People
1,220 worldwide
Run by
AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00
Phase 1/2Taking people
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Where
Chuo Ku, Fukuoka, Kashiwa, Nagoya, Sakai
Age
18 years and over
People
138 worldwide
Run by
Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00
Phase 1Taking people
A Study of ZW251 in Participants With Advanced Solid Tumors
Where
Kashiwa, Kyoto, Osaka, Tokyo
Age
18 years and over
People
140 worldwide
Run by
Zymeworks BC Inc.
See details and how to joinNCT07164313
Phase 2Taking people
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Where
Chūōku, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00
Phase 3Taking people
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Where
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi, Takatsuki-shi, Ube, Yokohama
Age
18 years and over
People
1,100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Where
Chuo-Ku, Hirakata-shi, Kashiwa-shi
Age
18 years and over
People
232 worldwide
Run by
AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00
Phase 1/2Taking people
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Where
Chuo Ku, Kashiwa-shi, Koto-ku
Age
18 years and over
People
150 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07488676
Phase 1/2Taking people
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Where
Bunkyoku, Kōtoku, Sakai
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00
Phase 2Taking people
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Where
Kashiwa-shi, Nagasaki, Nagoya, Osaka-Fu, Sendai
Age
18 years and over
People
120 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00
Phase 1Taking people
AB122 Platform Study
Where
Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo, Wakayama
Age
18 years and over
People
917
Run by
Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04999761
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Kashiwa, Nagaizumi-chō
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 3Taking people
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Where
Aichi, Fukuoka, Hokkaido, Kanagawa, Miyagi, Osaka, Tokyo, Toyama, Wakayama
Age
18 years and over
People
784 worldwide
Run by
Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT07710885